EyeGene Inc. (KOSDAQ:A185490) announced a private placement of 2nd series non-separable private equity bonds with no guarantee of interest bonds for gross proceeds of KRW 22,000,000,000 on September 16, 2020. The transaction include participation from Hanyang Securities Co. Ltd. (KOSE:A001750) for KRW 5,000,000,000, SUSUNG ASSET MANAGEMENT Co., Ltd. for KRW 1,000,000,000, Suseong KOSDAQ Venture M4 Specialized Investment Private Equity Investment Trust, a fund managed by Mirae Asset Daewoo Co., Ltd. (KOSE:A006800) for KRW 700,000,000, Suseong KOSDAQ Venture M2 Professional Investment Private Equity Investment Trust, a fund managed by Mirae Asset Daewoo Co., Ltd. (KOSE:A006800) for KRW 1,000,000,000, Suseong KOSDAQ Venture M3 Professional Investment Private Equity Investment Trust, a fund managed by Mirae Asset Daewoo Co., Ltd. (KOSE:A006800) for KRW 300,000,000, SP Mezzanine Private Equity Investment Trust No.

6, a fund managed by Samsung Securities Co.,Ltd. (KOSE:A016360) for KRW 2,000,000,000, Brain Kosdaq Venture Specialized Investment Criminal Private Equity Investment Trust No. 2, a fund managed by NH Investment & Securities Co., Ltd. (KOSE:A005940) for KRW 1,000,000,000, Hana Bank for KRW 1,000,000,000, NH Absolute Return Professional Investment Type Private Equity Trust No. 1, a fund managed by Samsung Securities Co., Ltd. for KRW 500,000,000, Korea Securities Finance Corporation, Investment Arm, EBEST Investment & Securities Co., Ltd. (KOSDAQ:A078020), Shinhan Investment Corp.

The bond would mature on September 18, 2025. The bond will be 100% convertible into 1,560,505 common shares for 11.81% stake of the company at a fixed conversion price of KRW 14,098 per share from September 18, 2021 to August 18, 2025. The transaction is expected to close on Sep 18, 2020.

The transaction has been approved by board of directors of the company.